COMBO-CAd: The COMBO CAD Study

Sponsor
Istituto Clinico Humanitas (Other)
Overall Status
Recruiting
CT.gov ID
NCT05141409
Collaborator
(none)
500
1
8.1
61.6

Study Details

Study Description

Brief Summary

Implementation of clinical strategies based on optical diagnosis of <5 mm colorectal polyps may lead to a substantial saving of economic and financial resources. Despite this, 84.2% of European endoscopists reported not to use such strategies - also named as leave-in situ and resect- and-discard - in their practice due to the fear of an incorrect optical diagnosis.

Indeed, accuracy of optical diagnosis is operator-dependent, and values reported in the community setting are below the safety thresholds proposed for its incorporation in clinical practice.

Artificial intelligence (AI) is being increasingly explored in different domains of medicine, particularly those entailing image analysis. As optical diagnosis involves subitaneous processing of multiple images, searching for specific visual clues, and recognizing well-defined visual patterns, AI systems has the potential to help endoscopists in distinguish neoplastic from non-neoplastic polyps, making the characterization process more reliable and objective. Computer-Aided-Diagnosis systems aiming at characterization are called CADx.

Preliminary data on CADx showed a high feasibility and accuracy of AI for optical diagnosis of colorectal polyp, and initial experiences in clinical practice confirmed preliminary results.

To assess the potential benefit and risk of AI-assisted optical diagnosis with standard colonoscopy, we exploited two new Computer-Aided-Diagnosis systems (CAD-EYE® Fujifilm Co., and GI-Genius® Medtronic) that provide the endoscopist with a real-time polyp characterization without the need of optical magnification.

Condition or Disease Intervention/Treatment Phase
  • Device: Artificial Intelligence

Study Design

Study Type:
Observational
Anticipated Enrollment :
500 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
The COMBO CAD Study: Characterization cOMparison Between twO CAD Systems
Actual Study Start Date :
Jan 26, 2022
Anticipated Primary Completion Date :
Sep 30, 2022
Anticipated Study Completion Date :
Sep 30, 2022

Arms and Interventions

Arm Intervention/Treatment
CAD-A

Device: Artificial Intelligence
Artificial Intelligence

CAD-B

Device: Artificial Intelligence
Artificial Intelligence

Outcome Measures

Primary Outcome Measures

  1. AI-assisted optical diagnosis performance [6 Months]

    AI-assisted optical diagnosis performance

Secondary Outcome Measures

  1. AI alone optical diagnosis performance [6 Months]

    AI alone optical diagnosis performance

Eligibility Criteria

Criteria

Ages Eligible for Study:
40 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • All patients aged 40 or older undergoing a colonoscopy for gastrointestinal symptoms, fecal immunohistochemical test positivity, primary screening or post-polypectomy surveillance
Exclusion Criteria:
  • subjects with personal history of CRC, or IBD.

  • Subjects affected with Lynch syndrome or Familiar Adenomatous Polyposis.

  • patients with inadequate bowel preparation (defined as Boston Bowel Preparation Scale < 2 in any colonic segment).

  • patients with previous colonic resection.

  • patients on antithrombotic therapy, precluding polyp resection.

  • patients who were not able or refused to give informed written consent.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Gastroenterology, Humanitas Research Hospital Rozzano Milano Italy 20089

Sponsors and Collaborators

  • Istituto Clinico Humanitas

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Istituto Clinico Humanitas
ClinicalTrials.gov Identifier:
NCT05141409
Other Study ID Numbers:
  • 11
First Posted:
Dec 2, 2021
Last Update Posted:
Feb 22, 2022
Last Verified:
Feb 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Feb 22, 2022